 |
|
|
| |
Early versus delayed hepatitis C treatment provides increased health benefits at lower costs:
A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients
|
| |
| |
from Jules: look at Figure 2 just below - treating very early - at F0-1 provides the best outcome for patients - it reduces risk MUCH MORE compared to treating at F2/3 - almost eliminates & reduces risk by 3-4 fold DCC [liver decompensation] , HCC [liver cancer] and LrD [liver related death]. When comparing treating at F0/1 versus F-4 risks are reduced 7- to 20-fold !!!!
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Yuri Sanchez Gonzalez1, Andy Ingram1, Claire Lindsay1, Hélène Parisé2, Suchin Virabhak2
1AbbVie Inc., North Chicago, IL, USA; 2Medicus Economics, Boston, MA, USA
|
| |
|
|
|
|
|
